{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T13:29:14Z","timestamp":1784813354813,"version":"3.55.0"},"reference-count":14,"publisher":"Scientific Scholar","issue":"5-6","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,5]]},"abstract":"<jats:sec>\n            <jats:title>Background &amp; objectives:<\/jats:title>\n            <jats:p>Vaccination against SARS-CoV-2 is a recommendation from the World Health Organization as the foremost preference in the current situation to control the COVID-19 pandemic. BBV152 is one of the approved vaccines against SARS-CoV-2 in India. In this study, we determined SARS-CoV-2\u2013specific antibody levels at day 0 (baseline, before vaccination), day 28 \u00b1 2 post-first dose (month 1) and day 56 \u00b1 2 post-first dose (month 2) of BBV152 whole-virion\u2013inactivated SARS-CoV-2 recipients, and compared the antibody responses of individuals with confirmed pre-vaccination SARS-CoV-2 infection to those individuals without prior evidence of infection.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>Blood samples were collected from 114 healthcare professionals and frontline workers who received BBV152 vaccine from February to May &amp; June 2021. Prior infection with SARS-CoV-2 was determined at baseline. Serum samples were used to estimate SARS-CoV-2 nucleoprotein-specific IgG [IgG (N)], spike protein-specific IgG [IgG (S)] and neutralizing antibodies (NAb).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Participants with previous SARS-CoV-2 infection after a single vaccine dose elicited IgG (N) and IgG (S) antibody levels along with NAb binding inhibition responses levels were similar to infection-na\u00efve vaccinated participants who had taken two doses of vaccine.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Interpretation &amp; conclusions:<\/jats:title>\n            <jats:p>Our preliminary data suggested that a single dose of BBV152-induced humoral immunity in previously infected individuals was equivalent to two doses of the vaccine in infection-na\u00efve individuals. However, these findings need to be confirmed with large sized cohort studies.<\/jats:p>\n          <\/jats:sec>","DOI":"10.4103\/ijmr.ijmr_2066_21","type":"journal-article","created":{"date-parts":[[2021,9,14]],"date-time":"2021-09-14T14:25:58Z","timestamp":1631629558000},"page":"671-676","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":12,"title":["Antibody responses to the BBV152 vaccine in individuals previously infected with SARS-CoV-2"],"prefix":"10.25259","volume":"153","author":[{"given":"Nathella Pavan","family":"Kumar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Padmapriyadarsini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K. R.","family":"Uma Devi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V. V.","family":"Banurekha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arul","family":"Nancy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. P.","family":"Girish Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manoj V.","family":"Murhekar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nivedita","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samiran","family":"Panda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subash","family":"Babu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Balram","family":"Bhargava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10894","reference":[{"key":"R1-26-20241212","doi-asserted-by":"crossref","first-page":"102298","DOI":"10.1016\/j.isci.2021.102298","article-title":"Th1 skewed immune response of whole virion inactivated SARS-CoV-2 vaccine and its safety evaluation","volume":"24","author":"Ganneru","year":"2021","journal-title":"iScience"},{"key":"R2-26-20241212","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.jaci.2012.02.042","article-title":"Imidazoquinoline Toll-like receptor 8 agonists activate human newborn monocytes and dendritic cells through adenosine-refractory and caspase-1-dependent pathways","volume":"130","author":"Philbin","year":"2012","journal-title":"J Allergy Clin Immunol"},{"key":"R3-26-20241212","doi-asserted-by":"crossref","first-page":"e43612","DOI":"10.1371\/journal.pone.0043612","article-title":"Potent adjuvanticity of a pure TLR7-agonistic imidazoquinoline dendrimer","volume":"7","author":"Shukla","year":"2012","journal-title":"PLoS One"},{"key":"R4-26-20241212","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/S1473-3099(20)30942-7","article-title":"Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: A double-blind, randomised, phase 1 trial","volume":"21","author":"Ella","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"R5-26-20241212","doi-asserted-by":"crossref","first-page":"103401","DOI":"10.1016\/j.ebiom.2021.103401","article-title":"SARS-CoV-2 vaccines for all but a single dose for COVID-19 survivors","volume":"68","author":"Frieman","year":"2021","journal-title":"EBioMedicine"},{"key":"R6-26-20241212","doi-asserted-by":"crossref","first-page":"eabf4063","DOI":"10.1126\/science.abf4063","article-title":"Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection","volume":"371","author":"Dan","year":"2021","journal-title":"Science"},{"key":"R7-26-20241212","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/j.immuni.2020.10.004","article-title":"Orthogonal SARS-CoV-2 serological assays enable surveillance of low-prevalence communities and reveal durable humoral immunity","volume":"53","author":"Ripperger","year":"2020","journal-title":"Immunity"},{"key":"R8-26-20241212","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/s41586-020-2550-z","article-title":"SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls","volume":"584","author":"Le Bert","year":"2020","journal-title":"Nature"},{"key":"R9-26-20241212","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1056\/NEJMc2101667","article-title":"Antibody responses in seropositive persons after a single dose of SARS-CoV-2 mRNA Vaccine","volume":"384","author":"Krammer","year":"2021","journal-title":"N Engl J Med"},{"key":"R10-26-20241212","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1038\/s41586-021-03324-6","article-title":"mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants","volume":"592","author":"Wang","year":"2021","journal-title":"Nature"},{"key":"R11-26-20241212","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.ijid.2021.05.034","article-title":"Immunological memory and neutralizing activity to a single dose of COVID-19 vaccine in previously infected individuals","volume":"108","author":"Sasikala","year":"2021","journal-title":"Int J Infect Dis"},{"key":"R12-26-20241212","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1016\/S0140-6736(21)00501-8","article-title":"Antibody response to first BNT162b2 dose in previously SARS-CoV-2-infected individuals","volume":"397","author":"Manisty","year":"2021","journal-title":"Lancet"},{"key":"R13-26-20241212","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1016\/S0140-6736(21)00502-X","article-title":"Effect of previous SARS-CoV-2 infection on humoral and T-cell responses to single-dose BNT162b2 vaccine","volume":"397","author":"Prendecki","year":"2021","journal-title":"Lancet"},{"key":"R14-26-20241212","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1093\/ageing\/afaa274","article-title":"Efficacy and safety of COVID-19 vaccines in older people","volume":"50","author":"Soiza","year":"2021","journal-title":"Age Ageing"}],"container-title":["Indian Journal of Medical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.4103\/ijmr.IJMR_2066_21","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T23:03:58Z","timestamp":1751497438000},"score":1,"resource":{"primary":{"URL":"https:\/\/ijmr.org.in\/antibody-responses-to-the-bbv152-vaccine-in-individuals-previously-infected-with-sars-cov-2-a-pilot-study\/"}},"subtitle":["A pilot study"],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":14,"journal-issue":{"issue":"5-6","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.4103\/ijmr.ijmr_2066_21","relation":{},"ISSN":["0971-5916"],"issn-type":[{"value":"0971-5916","type":"print"}],"subject":[],"published":{"date-parts":[[2021,5]]}}}